Extended Data Fig. 7: 22RV1 cells are resistant to ABBV-744.
From: Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
a, ABBV-075 but not ABBV-744 induces a robust dose-dependent increase of senescent (β-galactosidase-positive) 22RV1 cells after 7 days of treatment. Data are mean ± s.d. (n = 3 biological replicates) and are representative of n = 2 independent experiments. b, Scatter plot of gene expression changes (n = 2) caused by ABBV-075 (60 nM) or ABBV-744 (90 nM) treatment for 24 h in DHT-stimulated 22RV1 cells. Statistical analysis of fold change (FC) > 2.0, P < 0.01 was conducted using the DESeq2 method. c, Split violin representation of DHT-regulated compared with all differentially expressed genes in 22RV1 from RNA-seq as shown in b. The long solid line represents the mean fold change. The small lines represent individual data points. The dotted line represents the overall average. Statistical significance between all versus DHT was determined by two-tailed unpaired Student’s t-test and P < 0.01 by DESeq2. ABBV-075 affects both DHT and a broad distribution of genes, whereas ABBV-744 has a more limited effect on both DHT-stimulated genes and overall. d, ABBV-075 but not ABBV-744 negatively regulated the androgen response in 22RV1 cells as shown by gene set enrichment analysis. NES > 2.0, q < 0.05 calculated using FDR (Benjamini–Hochberg correction). e, H3K27Ac and BRD4 ChIP–seq heat maps at transcription start sites and enhancers in 22RV1 cells. f, ABBV-744 less effectively displaces BRD4 from super-enhancers in the resistant 22RV1 cell line compared with sensitive LNCaP cells.
